In a conversation with Tim Ferriss, neuroscientist and podcaster Dr. Andrew Huberman turned his attention to a developing area within the peptide space: the use of low-dose GLP-1 receptor agonists, not for weight loss, but for cognitive well-being and neuroprotection.
Huberman was candid that he has not personally tried any GLP-1s but said he finds the direction compelling.
“I’ve never used a GLP. I’m kind of curious because a lot of people are talking about low-dose tirzepatide or retatrutide, like a tenth of the prescribed dose, for not just weight loss but for just cognitive well-being,” he said.
Ferriss quickly flagged “neuroprotective effects” as an area of active interest, and Huberman agreed: “Neuroprotective effects, maybe other things.”
The scientific interest here runs along two main lines. The first involves correcting insulin resistance as a pathway to brain protection.
As Ferriss put it, “If you take someone who has insulin resistance or is on the path to insulin resistance and you correct for that, then that in and of itself on some level should be neuroprotective, right? Especially if you’re looking at vascular dementia or any number of things.”
The second possibility is that GLP-1s could act on the brain through mechanisms entirely independent of their metabolic function. Huberman acknowledged he had not yet read the relevant literature on that specific question but said the distinction matters: the cognitive case becomes much stronger if the effect does not rely solely on correcting metabolic dysfunction.
One concrete example that surfaced during the exchange was intraocular pressure. Huberman noted there is “some interesting data that tirzepatide may reduce eye pressure,” raising the possibility of a benefit in conditions such as glaucoma.
For context on how these comp0unds work at different doses, Huberman explained that GLP-1 dr*gs designed to raise GLP levels roughly 100-fold were originally used to treat type 2 diabetes and produced little weight loss.
The formulations that raise GLP levels thousandfold or more generate the significant weight reduction now widely associated with this d*ug class, though that comes with potential muscle loss as a downside. Tirzepatide and retatrutide, which also target the GIP and glucagon systems, appear to be even more potent.
Ferriss flagged retatrutide specifically as one to approach carefully: “Careful with that one, kiddos.”
The pattern of microdosing these comp0unds has grown out of this landscape. “A lot of people are finding that microdoses can have similar effects,” Huberman observed, framing it as “an important kind of cost-risk analysis” for those interested in the cognitive angle without the full metabolic impact.
What Huberman made clear is that this remains an exploratory area. The clinical data are limited, but the question of whether GLP-1s can support cognitive health independent of their effects on weight is one that researchers and self-experimenters are actively pursuing.
